Prognostic value of quality of life measured after treatment on subsequent survival in patients with nasopharyngeal carcinoma
- 293 Downloads
Pretreatment quality of life (QoL) has been used to predict survival in cancer patients. In this study, we examined the prognostic value of QoL measured after treatment on subsequent survival in patients with nasopharyngeal carcinoma (NPC).
We enrolled 273 patients with NPC who had been curatively treated for more than 1 year. The EORTC QLQ-C30 and H&N35 questionnaires were completed 1 year after radiotherapy. The predictability of QoL variables on disease-specific survival (DSS) and overall survival (OS) was analyzed using Cox’s proportional hazards models.
Twenty-nine (10.6 %) patients developed locoregional relapse and 27 (9.9 %) had distant metastasis after the QoL survey with subsequent 5-year DSS and OS rates of 87.9 % and 84.0 %, respectively. Based on the QLQ-C30, scales of physical functioning, fatigue, and appetite loss significantly predicted DSS and OS (p < 0.05). In the H&N35, only sexuality was significantly correlated with DSS and OS (p < 0.05). An increment of 10 points in physical functioning (HR: 0.69; 95 % CI: 0.48–0.90; p = 0.004) or a decline of 10 points in fatigue problems (HR: 1.40; 95 % CI: 1.19–1.61; p = 0.0002), appetite loss (HR: 1.21; 95 % CI: 1.03–1.40; p = 0.02), and sexuality (HR: 1.14; 95 % CI: 1.02–1.25; p = 0.019) was associated with better OS.
Some QoL variables measured after the treatment provide prognostic value on subsequent survival in patients with NPC.
KeywordsQuality of life Nasopharyngeal carcinoma EORTC QLQ-C30 H&N35 Subsequent survival
European organization of research and treatment of cancer
Supported by Grant “NSC 90-2320-B-182A-006-” from the National Science Council, Taiwan; “CMRPG860502” and “CMRPG860503” from the Chang Gung Memorial Hospital, Taiwan.
Conflict of interest
No financial disclosure from any author.
- 1.Cancer registry annual report in Taiwan area. (2008). Department of Health, Executive Yuan, Republic of China 2011.Google Scholar
- 2.Jen, Y., Shih, R., Lin, Y., Su, W., Ku, C., Chang, C., et al. (2005). Parotid gland-sparing 3-dimensional conformal radiotherapy results in less severe dry mouth in nasopharyngeal cancer patients: A dosimetric and clinical comparison with conventional radiotherapy. Radiotherapy and Oncology, 75(2), 204–209.PubMedCrossRefGoogle Scholar
- 4.Hsiung, C., Ting, H., Huang, H., Lee, C., Huang, E., & Hsu, H. (2006). Parotid-sparing intensity-modulated radiotherapy (IMRT) for nasopharyngeal carcinoma: Preserved parotid function after IMRT on quantitative scintigraphy and comparison with historical data after conventional radiotherapy. International Journal of Radiation Oncology Biology Physics, 66(2), 454–461.CrossRefGoogle Scholar
- 6.Sultanem, K., Shu, H., Xia, P., Akazawa, C., Quivey, J., Verhey, L., et al. (2000). Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: The University of California-San Francisco experience. International Journal of Radiation Oncology Biology Physics, 48(3), 711–722.CrossRefGoogle Scholar
- 7.Lee, N., Harris, J., Garden, A., Straube, W., Glisson, B., Xia, P., et al. (2009). Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: Radiation therapy oncology group phase II trial 0225. Journal of Clinical Oncology, 27(22), 3684–3690.PubMedCrossRefGoogle Scholar
- 11.Langendijk, H., Aaronson, N., de Jong, J., ten Velde, G., Muller, M., & Wouters, M. (2000). The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. Radiotherapy and Oncology, 55(1), 19–25.PubMedCrossRefGoogle Scholar
- 14.Efficace, F., Therasse, P., Piccart, M., Coens, C., van Steen, K., Welnicka-Jaskiewicz, M., et al. (2004). Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: An international multicenter study. Journal of Clinical Oncology, 22(16), 3381–3384.PubMedCrossRefGoogle Scholar
- 22.Aaronson, N., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N., et al. (1993). The european organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.PubMedCrossRefGoogle Scholar
- 25.Fang, F., Chien, C., Tsai, W., Chen, H., Hsu, H., Lui, C., et al. (2008). Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy versus intensity-modulated radiotherapy—A longitudinal study. International Journal of Radiation Oncology Biology Physics, 72(2), 356–364.CrossRefGoogle Scholar
- 27.Bjordal, K., Hammerlid, E., Ahlner-Elmqvist, M., de Graeff, A., Boysen, M., Evensen, J., et al. (1999). Quality of life in head and neck cancer patients: Validation of the European organization for research and treatment of cancer quality of life questionnaire-H&N35. Journal of Clinical Oncology, 17(3), 1008–1019.PubMedGoogle Scholar
- 28.Fayers, P., Aaronson, K., & Bjordal, K. (2002). EORTC QLQ-C30 scoring manual (2nd ed., p. 1999). Brussels: EORTC Data Center.Google Scholar